FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to non-natural NKG2D receptors associated with mammalian cell surfaces and can be used to deliver a payload to a T-cell, macrophage or NK-cell of a mammal. Disclosed is a non-natural modified NKG2D receptor, which contains an amino acid sequence selected from SEQ ID NO: 18–35.
EFFECT: invention provides obtaining non-natural NKG2D receptors binding to non-natural, modified domains α1-α2 ligands NKG2D, but not with natural ligands NKG2D, containing SEQ ID NO: 4.
6 cl, 24 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| TRUNCATED CHIMERIC RECEPTORS NKG2D AND THEIR WAYS OF USE IN IMMUNOTHERAPY USING NATURAL KILLER CELLS | 2018 |
|
RU2830556C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
